Use of nalotone to to reverse narcotic respiratory depression in the newborn infant.

Twenty neonates whose mothers had received meperidine (1.0 to 1.5 mg/kg) intravenously within three hours of delivery were studied to determine the effectiveness of naloxone in reversing neonatal respiratory depression. The following measurements were carried out within 20 to 30 minutes after delivery: minute ventilation, end tidal CO2, and ventilatory response to CO2. These determinations were repeated after administration of either placebo or naloxone, 0.01 mg/kg intramuscularly. Minute ventilation and PAco were within a normal range before medication in both groups, but the slope of the CO2 response curve was decreased, indicating mild-to-moderate respiratory depression. After administration of placebo the test results did not change significantly. After administration of naloxone, VE increased significantly (P less than 0.05) and the slope of the CO2 response curve doubled (P less than 0.001). Naloxone effectively reverses narcotic depression of the respiratory center in the newborn infant.     

Pharmacokinetic profile of caffeine in the premature newborn infant with apnea.

The pharmacokinetic profile of caffeine was studied in 32 premature newborn infants with apnea: 12 following a single intravenous dose; 3 after a single oral dose; 7 during treatment with an initial empirical (high) maintenance dose schedule; and 10 during treatment with a revised (lower) dose schedule. Mean (+/- SE) AV d, t 1/2, ke1, and clearance following a single intravenous dose were 0.916 +/- 0.070 1/kg, 102.9 +/- 17.9 hours, 0.009 +/- 0.001/hours and 8.9 +/- 1.5 ml/kg/hour, respectively. Rapid absorption was noted with plasma concentrations of 6 to 10 mg/l achieved within 30 minutes to two hours following an oral dose of 10 mg/kg. Cpss of caffeine in infants given a high empirical dose (11.2 +/- 1.5 mg/kg/day) ranged from 22.5 to 84.2 mg/l (mean = 45.3) whereas a dose schedule based on kinetic data (2.5 mg/kg/day) yielded plasma concentrations ranging from 7.4 to 19.4 mg/l (mean = 13.7). We suggest a loading dose of 10 mg/kg intravenously or orally followed by a daily maintenance dose of 2.5 mg/kg/day administered as a single dose for the treatment and prevention of neonatal apnea.     

Biochemical characteristics of "young" and "old" erythrocytes of the newborn infant.

Cord blood samples from ten term infants were fractionated into populations of young and old erythrocytes and compared with cells prepared in a similar fashion from eight normal adults. The old cell fraction from the newborn infants had very low phosphofructokinase activity and did not display the usual decline of activity of the enzymes phosphoglycerate kinase and enolase. In addition, the old cells from the newborn infants demonstrated impaired glucose consumption, which, upon analysis of the pattern of glycolytic intermediates, appeared to be a result of the phosphofructokinase deficiency. These findings suggest that cells produced earlier in gestation possess the developmental characteristics of fetal blood to a more significant degree and that these biochemical alterations may produce functional impairment.     

Antimicrobial therapy of bacterial sepsis in the newborn infant

Septicemia continues to be an important cause of neonatal morbidity and mortality. The bacteria most commonly responsible are group B beta-hemolytic streptococci and Escherichia coli, but regional differences exist. Recently sepsis caused by Staphylococcus epidermidis has occurred with increasing frequency in several neonatal intensive care units. Other organisms are less commonly responsible. The choice of antibiotics for suspected sepsis is based on the possible organisms involved and their antibiotic susceptibility patterns, which vary from hospital to hospital and at different times in the same hospital. Currently recommended initial therapy consists of a penicillin and an aminoglycoside, usually ampicillin and gentamicin. The addition of vancomycin is indicated when staphylococcal septicemia is suspected. During outbreaks of neonatal sepsis caused by aminoglycoside-resistant gram-negative bacteria, the use of third-generation cephalosporins or acylaminopenicillins may be appropriate, depending on the results of susceptibility tests. Continuing efforts to develop antibiotics for the treatment of neonatal sepsis are warranted.     

Thrombosis of the left coronary artery in a newborn infant

A unique occurrence of antenatal thrombosis of the left main coronary artery in a term infant is presented. The clinical features are indistinguishable from those of several other forms of congenital heart disease. The etiology of the thrombosis is unknown.     

Estimation of PaCO2 by two noninvasive methods in the critically ill newborn infant

Simultaneous measurements of arterial, transcutaneous, and peak expired carbon dioxide were obtained in 24 newborn infants receiving mechanical ventilation during the first week after birth. Two calibration algorithms designed to estimate PaCO2 from the noninvasive measurements were then examined. Both approaches entailed finding a statistical relationship by which future noninvasive measurement could be used to estimate the arterial value rather then measuring it directly. The first utilized the difference between the initial paired measurements (an in vivo calibration); the second used the mean difference between all measurements in the population. Adjusted tcPCO2 measurements by either the in vivo calibration or by the population-based factor led to estimates of PaCO2 with 95% confidence limits of +/- 6 to +/- 8 torr. In contrast, this degree of precision for the peak expired CO2 measurement was only possible using the in vivo calibration method. The use of an airway adaptor for PCO2 measurement led to CO2 retention in more than half of the infants. Transcutaneous monitoring had no significant effects on the infants, but was hampered by excessive drift and erratic sensitivity of the electrodes.     

Development of the capacity to produce specific antibody to an ingested food antigen in the premature infant.

Thirteen premature infants were given bovine serum albumin, a cow milk protein, by addition to their formula. Serum antibodies to BSA developed in three infants 36-38 weeks' gestation, confirming that exposure to the antigen in the gastrointestinal tract will immunize infants born after 36 or more weeks' gestation. Serum antibodies to BSA, however, were detected in only one of two infants of 35 weeks' and in none of eight infants of 30-34 weeks' gestation. The results show that the capacity to make specific antibodies to BSA develops around 35-36 weeks' gestation, despite the prior appearance of organized lymphoid tissue and independent of antigen exposure.